title: The effect of various hypoglycaemic sulphonylureas on the cardiotoxicity of glycosides and arrhythmogenic activity due to myocardial ischaemia.
abstract: The effects of different sulphonylureas on the electrical cardiac activity were studied in 145 rabbits and in 103 rats as well as in 278 digitalis-treated, non-smoker non-insulin-dependent diabetics on the same therapy at least during the previous three months. In rabbits and rats glibenclamide (0.0032-100 mumol. kg-1) decreased, while tolbutamide and carbutamide (0.008-1000 mumol. kg-1) increased strophantidin toxicity and myocardial ischaemia induced transitory ventricular fibrillation dose-dependently. The differences between the dose-response curve of glibenclamide and those of tolbutamide or carbutamide were significant. In digitalized non-insulin-dependent diabetics, multifocal ectopic ventricular beats could be observed in none among the 80 glibenclamide-treated diabetics, while in 12 cases of the 71 tolbutamide and in 10 cases of the 61 carbutamide treated diabetics. Two of the 66 non-insulin-dependent diabetics receiving only diet and 7 of the 278 age and sex matched, non-smoker, metabolically healthy patients had multifocal ectopic ventricular beats. No significant difference could be found between the therapeutical groups. It was concluded that instead of tolbutamide, glibenclamide must be preferred in digitalis-treated diabetics, when metabolic control is not satisfactorily achieved by diet and regime alone.
authors.affiliation: National Institute of Cardiology, Budapest, Hungary.
authors.forename: G
authors.initials: G
authors.lastname: Pogátsa
authors.forename: M Z
authors.initials: MZ
authors.lastname: Koltai
authors.forename: I
authors.initials: I
authors.lastname: Balkányi
authors.forename: I
authors.initials: I
authors.lastname: Dévai
authors.forename: V
authors.initials: V
authors.lastname: Kiss
authors.forename: A
authors.initials: A
authors.lastname: Köszeghy
mesh_terms: D000818:Animals; D001145:Arrhythmias, Cardiac / Q000209:etiology*; D001786:Blood Glucose / Q000378:metabolism; D003327:Coronary Disease / Q000209:etiology*; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D004071:Digitalis Glycosides / Q000009:adverse effects; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male; D011188:Potassium / Q000097:blood; D011817:Rabbits; D051381:Rats; D012189:Retrospective Studies; D013327:Strophanthidin / Q000633:toxicity; D013453:Sulfonylurea Compounds / Q000009:adverse effects*; D014693:Ventricular Fibrillation / Q000209:etiology
chemical_list: D001786:Blood Glucose; D004071:Digitalis Glycosides; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D013327:Strophanthidin; D011188:Potassium